

**124.201A Cannabis-derived products — rules.**

1. If a cannabis-derived investigational product approved as a prescription drug medication by the United States food and drug administration is added to the federal schedule of controlled substances by the federal drug enforcement administration and notice of the addition is given to the board, the board shall similarly add the prescription drug medication in the schedule of controlled substances under [this chapter](#).

2. If a cannabis-derived product approved as a prescription drug medication by the United States food and drug administration is eliminated from or revised in the federal schedule of controlled substances by the federal drug enforcement administration and notice of the elimination or revision is given to the board, the board shall similarly eliminate or revise the prescription drug medication in the schedule of controlled substances under [this chapter](#).

3. The board shall adopt rules pursuant to [chapter 17A](#) to administer [this section](#). The board may adopt rules on an emergency basis as provided in [section 17A.4, subsection 3](#), and [section 17A.5, subsection 2](#), to administer [this section](#), and the rules shall be effective immediately upon filing unless a later date is specified in the rules. Any emergency rules adopted in accordance with [this section](#) shall also be published as a notice of intended action as provided in [section 17A.4, subsection 1](#).

4. Any cannabis-derived investigational product or cannabis-derived product approved as a prescription drug medication by the United States food and drug administration shall not be considered marijuana or cannabimimetic agents, both as defined in [section 124.204](#), tetrahydrocannabinols as used in [section 124.204, subsection 4](#), paragraph “u”, unnumbered paragraph 1, or hemp as defined in [section 204.2](#).

[2017 Acts, ch 162, §1, 25; 2020 Acts, ch 1023, §1, 13](#)